Clinical Trials Logo

Filter by:
NCT ID: NCT06221371 Recruiting - Clinical trials for Ischemic Stroke, Acute

Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion

TNK-PLUS
Start date: December 16, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy of endovascular treatment with or without preceding intravenous Tenecteplase in patients with late-window (4.5-24 hours of symptom onset) acute ischemic stroke due to middle cerebral artery (MCA) M1 or M2 occlusion.

NCT ID: NCT06221267 Recruiting - Migraine Clinical Trials

A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area

Start date: January 26, 2024
Phase:
Study type: Observational [Patient Registry]

This study is a single-arm, prospective, multicenter, observational registry study. It plans to enroll 120 migraine patients who meet the inclusion criteria and are treated with rimegepant in selected hospital outpatient clinics in the Greater Bay Area. The main purpose of this study is to observe the effectiveness of rimegepant in treating migraines in a real-world clinical setting, including the impact of rimegepant on the quality of life, functioning, productivity status of migraine patients, and patients' satisfaction with the use of rimegepant in treating migraines.

NCT ID: NCT06221241 Recruiting - Clinical trials for Diabetic Peripheral Neuropathic Pain

Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain

Start date: March 25, 2024
Phase: Phase 2
Study type: Interventional

A Phase 2, Multicenter, Randomized, Double-blind, Placebo and Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX000623 in Participants with Diabetic Peripheral Neuropathic Pain

NCT ID: NCT06221215 Recruiting - Clinical trials for Brain Injury Traumatic Diffuse With Loss of Consciousness

Clinical Analysis of Early Hormones Between Patients With Traumatic Brain Injury and Cerebral Hemorrhage

Start date: October 1, 2023
Phase:
Study type: Observational [Patient Registry]

Our understanding of neurosecretory dysfunction after TBI is still insufficient, and the number of patients with neuroendocrine dysfunction caused by craniocerebral trauma may be underestimated, especially the neuroendocrine changes related to HPA axis in the early stage after craniocerebral trauma. Moreover, there are few and fragmentary literature data on the benefits of hormone replacement therapy in patients with neuroendocrine disorders after traumatic brain injury. This requires more studies to further determine the characteristics of pituitary function or hormone disorders in the early stage after traumatic brain injury, which makes it necessary for us to further study the neuroendocrine dysfunction (hormone disorder) in the early stage after craniocerebral injury. To explore the relationship between craniocerebral injury and early hormone disorder by measuring the changes of early hormone levels in patients with TBI is of great significance for the early detection of related complications after craniocerebral injury and the evaluation of the prognosis of patients with craniocerebral injury, and can provide a new diagnosis and treatment plan for early intervention of related complications after TBI.

NCT ID: NCT06221059 Recruiting - Clinical trials for Chronic Kidney Disease

Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease

Start date: March 2, 2024
Phase: Phase 2
Study type: Interventional

The objective of this study was to evaluate the efficacy of HRS-1780 tablets or Henagliflozin Proline tablets in patients with chronic kidney disease by evaluating UACR change from baseline to Week 13

NCT ID: NCT06220838 Recruiting - Clinical trials for Advanced Solid Tumor

Study SC-101 in Subjects With Advanced Malignancies

Start date: February 27, 2024
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, pharmacokinetics, and anti-cancer efficacy of SC-101 in subjects with advanced or metastatic solid tumors.

NCT ID: NCT06220630 Recruiting - Breast Cancer Clinical Trials

The Characteristics, Treatment Patterns and Prognosis of Chinese Male Breast Cancer: A Real-world Study

Start date: August 1, 2021
Phase:
Study type: Observational

The goal of this observational study is to investigate the features in Chinese male breast cancer (MBC) patients. The main question it aims to answer is: - The characteristics, treatment patterns and prognosis of Chinese MBC patients. The clinicopathological characteristics, treatment information and follow-up data of participants will be extracted from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved Chinese centers. Researchers will investigate the features, survival associated factors and other relevant factors of this population.

NCT ID: NCT06220617 Recruiting - Colorectal Cancer Clinical Trials

Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)

Start date: January 11, 2024
Phase:
Study type: Observational

The primary objective of the study is to screen multi-omics markers in blood samples and construct a prediction model for CRC based on liquid biopsy, and we will further optimize the prediction model by validating its clinical performance externally.

NCT ID: NCT06220552 Recruiting - Clinical trials for Recurrent Glioblastoma

The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma

Start date: December 27, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of low-dose radiotherapy combined with programmed death 1 (PD-1) inhibitor (sintilimab) and temozolomide in recurrent glioblastoma. The eligible patients are scheduled to administered sintilimab 200mg D1 Q3W temozolomide 50mg/m2 QD and radiotherapy 1Gy/1F D1/D2/D8/D15 Q3W for 4-6 cycles, then sintilimab for maintenance. The overall primary study hypothesis is that the combination regimen of low-dose radiotherapy, sintilimab and temozolomide is safe and feasible in the treatment of recurrent glioblastoma.

NCT ID: NCT06220500 Recruiting - Clinical trials for Brucella Spondylitis

Radiomics Analysis Based on MRI to Detect Brucella Spondylitis

Start date: January 1, 2023
Phase:
Study type: Observational

Brucella spondylitis, an infectious spinal disease caused by the invasion of Brucella bacteria into the body. Its diagnosis relies mainly on laboratory and imaging tests. Due to the limited diagnostic ability of X-ray and CT for Brucella spondylitis, MRI has become the main diagnostic tool. In recent years, functional magnetic resonance technology has demonstrated great advantages in the diagnosis and therapeutic evaluation of brucellosis spondylitis, which can provide pathophysiologic information about the disease and is also a noninvasive and noninvasive diagnostic tool with a broader application prospect. Radiomics, an emerging approach, has also shown better diagnostic efficacy for this disease.